Investor Overview

Corporate Profile

HTG Molecular Diagnostics, Inc's. (“HTG”) mission is to empower precision medicine at the local level. In 2013, the company commercialized its HTG Edge instrument platform and a portfolio of multiplexed profiling panels that leverage HTG’s proprietary target protection chemistry. In 2014, the company launched the HTG EdgeSeq system that combines the power of HTG Edge chemistry and automation with NGS technology. The HTG EdgeSeq system enables fast and easy use of NGS instruments for molecular profiling.

Stock Quote

HTGM (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.04 (1.91%)
Data as of 08/21/17 11:35 a.m. ET

Recent News

HTG Molecular Diagnostics’ Technology to be Used in WIN Consortium NSCLC Clinical Trial
HTG Molecular Diagnostics Reports Second Quarter 2017 Results
HTG Molecular Diagnostics Announces Second Companion Diagnostic Development Project with QIAGEN
HTG Molecular Diagnostics to Present at the Canaccord Genuity Growth Conference
More News >>

Upcoming Events

There are currently no events scheduled.
More Events >>
Data provided by Nasdaq. Minimum 15 minutes delayed.

Shareholder Tools

Print Page Print Page   E-mail Page E-mail Page   RSS Feeds RSS Feeds   E-mail Alerts E-mail Alerts